تظاهرات روماتیسمی در میان بیماران مبتلا به سرطان که با مهارکننده های ایمنی کنترل می شوند

Our findings underscore that rheumatic iAE are part of the side effect profile of ICIs and require heightened awareness as these therapies are becoming the standard of care for various malignancies. We show that these appear later in the course of iAEs and respond preferentially to high dose steroids. MTX appears effective as a steroid sparing agent.